ACTRN12621000775819撤回1 期
A single dose, randomized, blinded, two-treatment, three period, three-sequence, partial replicate, reference scaled crossover study comparing a test formulation of Dimethyl (2E)-but-2-enedioate capsule in a 3 way crossover comparison against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting conditions in healthy male and female volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy males and non-pregnant female volunteers.
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 18.5 and 32
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Able to provide written informed consent
排除标准
- •Concomitant drug therapy of any kind
- •Any clinically significant medical conditions
- •Sensitive to the study drug
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Females who are pregnant and/or breastfeeding
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 60 days of the start of the study or donated blood within the 60 days preceding the study
- •Volunteers for whom the Clinical Investigator believer, for any reason, that participation would not be an acceptable risk
研究者
相似试验
撤回
1 期
Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fed conditions in healthy male and female volunteers.Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.Neurological - Multiple sclerosisACTRN12621000887875Zenith Technology Corporation Limited39
已完成
1 期
Comparative assessment of the absorption of a generic formulation of bexarotene capsule against the innovator bexarotene capsule conducted under fed conditions in healthy male volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of bexarotene with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, bexarotene is a member of a subclass of retinoids. Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL).Bioequivalence study conducted in healthy volunteers comparing two formulations of bexarotene with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, bexarotene is a member of a subclass of retinoids. Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL).Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12616000374460Zenith Technology Corp Ltd58
已完成
1 期
Comparative assessment of the absorption of a generic formulation of (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets against the innovator (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets conducted under fasting conditions in healthy male and female volunteers(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid is used for the treatment of management of demonstrated thyroid hormone deficiency.Metabolic and Endocrine - Thyroid diseaseACTRN12620000191998Zenith Technology Corporation Limited25
尚未招募
不适用
Bioequivalence study of Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg (fasting)CTRI/2022/06/043058Mylan Laboratories Limited
尚未招募
不适用
Bioequivalence study of Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditionsCTRI/2022/06/043078Mylan Laboratories Limited